menu search

Is abbvie still a good dividend stock to buy?

AbbVie's best-selling product lost patent-protected market exclusivity in the U.S. this year. Competition with lower-cost biosimilar versions of ...

October 31, 2023, 5:23 am

Abbvie surprises in 3q with better than expected humira sales

Abbvie (NYSE:ABBV) raised its 2023 profit guidance after a strong quarterly earnings report driven by demand for newer drugs and better-than-expected ...

October 27, 2023, 10:31 am

Abbvie's humira sales sink 36% but guidance lifted on growth from other drugs

AbbVie raises earnings guidance for fiscal 2023....

October 27, 2023, 8:28 am

Abbvie raises profit forecast after humira, newer drugs drive results beat

AbbVie on Friday raised its annual profit forecast after beating quarterly earnings estimates, helped by a lower-than-feared drop in sales of its bloc...

October 27, 2023, 7:42 am

Abbvie results beat expectations despite low-cost competition to blockbuster humira

AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook,...

October 27, 2023, 7:42 am

Novo nordisk milks the obesity cash cow - how long will it last?

NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, hum...

October 24, 2023, 9:30 am

Viatris: get paid 5%, before growth materializes

VTRS lost its humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the f...

October 20, 2023, 10:00 am

Abbvie: the humira loss may be fully priced in after all

The US FDA has already approved two directly interchangeable biosimilars to ABBV's humira, namely Boehr...

October 18, 2023, 11:00 am

Abbvie: q2 success sets the stage for consistent growth

AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio of products. The company's flagship product, ...

October 17, 2023, 1:58 pm

Abbvie: why you should pay attention to this high-yielding dividend king (rating downgrade)

Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being just one of four in the healthcare sector. The pharmaceuti...

October 17, 2023, 9:20 am

Abbvie: successfully navigating humira's patent cliff with 4% yield and 270% dgr since 2014

Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its parent company and the S&P 500, thanks to the s...

October 16, 2023, 10:44 am

Abbvie unleashed: 4% yield, potentially 40% undervalued

AbbVie has shown resilience and strength despite the patent loss of its best-selling drug, humira. The ...

September 4, 2023, 8:19 am

Abbvie: balance is everything

AbbVie's future growth depends on improving its balance of drugs offered, in contrast to its humira-dep...

September 4, 2023, 1:12 am

Could cvs make a copy of ozempic?

CVS is going to commercialize a biosimilar to humira. humira...

September 2, 2023, 7:35 am

Anchored in innovation: moonlake immunotherapeutics charts a new course (rating upgrade)

MoonLake Immunotherapeutics' financial health improved with $501.8M cash reserves and robust Q2 2023 research advancements. MLTX focuses on sonelokima...

August 27, 2023, 11:54 pm

3 surprisingly underrated stocks to buy right now

Investors aren't giving AbbVie nearly enough credit for its post-humira strategy. CRISPR Therapeutics' ...

August 26, 2023, 6:55 am

Can abbvie (abbv) protect revenues after humira patent loss?

AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost ...

August 24, 2023, 12:01 pm

Cvs health launches subsidiary to produce biosimilar drugs

CNBC's Bertha Coombs joins 'Closing Bell Overtime' to talk news that CVS Health is launching a subsidiary to make biosimilar drugs to ...

August 23, 2023, 5:32 pm

Cvs health launches biosimilars subsidiary, will commercialize humira competitor

CVS Health Corp. CVS, -0.97% said Wednesday that it has launched a new subsidiary that will work directly with drugmakers to co-produce and commercial...

August 23, 2023, 4:36 pm

Cvs pushes further into generic drugs with sandoz partnership for new discount humira

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years....

August 23, 2023, 4:18 pm


Search within

Pages Search Results: